Ribavirin treatment for possible bornavirus infection

Ribavirin treatment for patients with anti-bornavirus antibodies and treatment-resistent neuropsychiatric symptoms. - Ribavirin for possible bornavirus infection

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051180130

Enrollment

Registered

2019-03-18

Start date

2020-11-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia, affective disorders, dementia, others neuropsychiatric disorders

Interventions

Oral administration of riabvirin with the same doses as for hepatitis C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Seropositive for bornavirus Treatment-resistent neuropsychiatric symptoms

Exclusion criteria

Exclusion criteria: Hemoglobin concenration lower than 10 g/dl

Design outcomes

Primary

Measure	Time frame
Target symptoms will be decided individually	—

Secondary

Measure	Time frame
Other symptoms than the target symptoms	—

Contacts

Public ContactHidenori Matsunaga

Osaka General Medical Center

matsunagah@opho.jp+81-6-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026